安罗替尼在EP方案耐药的小细胞肺癌中的治疗疗效和不良反应分析

Anlotinib for EP regimen to resistant small cell lung cancer:analysis of the effectiveness and adverse reactions

目的探讨安罗替尼在EP方案耐药的小细胞肺癌中的疗效和安全性。方法选择2017年5月~2019年3月收治的小细胞肺癌患者共166例,根据治疗方法不同分为观察A组、观察B组和对照组。统计各组治疗的有效率、无进展生存期、重度不良反应发生率,通过病例对照研究比较分析观察组与对照组的组间差异。结果观察A组的有效率和无进展生存期均高于对照组(P <0.05),重度不良反应发生率除心血管事件外与对照组比较,差异无统计学意义(P> 0.05);观察B组的有效率和无进展生存期与对照组比较差异无统计学意义(P> 0.05),观察B组与对照组相比,虽增加了重度心血管事件的发生(P> 0.05),但减少了重度骨髓抑制的发生(P <0.05)。结论安罗替尼联合IC方案化疗能够提高EP方案耐药的小细胞肺癌的疗效,安罗替尼单药可应用于体力状态较差的EP方案耐药的小细胞肺癌,其不良反应可控,且有效延长了患者的无进展生存期,可考虑临床应用。

Objective To investigate the efficacy and safety of anlotinib in the treatment of small cell lung cancer resistant to EP regimen. Methods A total of 166 patients with small cell lung cancer treated in our hospital from May 2017 to March 2019 were collected and divided into observation group A,observation group B and control group according to different treatment methods.The effective rate, progression free survival period and the incidence of serious adverse reactions of each group were statistically analyzed.The differences between the observation group and the control group were compared and analyzed through case-control study. Results The effective rate and progression free survival time of group A were higher than those of control group(P < 0.05),and there was no significant difference in the incidence of severe adverse reactions between these two groups except for cardiovascular events(P > 0.05);There was no significant difference in the effective rate and progression free survival period between group B and control group(P > 0.05).Compared with the control group,the incidence of severe cardiovascular events increased in the observation group B(P > 0.05),but the incidence of severe myelosuppression decreased(P < 0.05). Conclusion Anlotinib combined with IC regimen chemotherapy can improve the efficacy of EP regimen resistant small cell lung cancer.Anlotinib alone can be used in the treatment of EP regimen resistant small cell lung cancer with poor physical strength.Its adverse reactions can be controlled and the progression free survival period of patients can be effectively prolonged,which can be clinically applied.